Proteomics International attended the Professional Society for Health Economics and Outcomes Research, Virtual ISPOR 2021, the world’s leading conference for health economics, from 17-20 May 2021. The event was attended by global healthcare leaders, including policy makers, payors and health economists.
The Company announced the results of an economic health benefit study for PromarkerD following comprehensive economic modelling and consultation with key industry stakeholders. The Company is set to seek a CPT Proprietary Laboratory Analyses (PLA) reimbursement code for its innovative PromarkerD test for diabetic kidney disease.
Proteomics International and Boston Healthcare Associates will present the modelling at the annual conference of the Professional Society for Health Economics and Outcomes Research, Virtual ISPOR 2021, the world’s leading conference for health economics, from 17-20 May 2021. The event is typically attended by global healthcare leaders, including policy makers, payors and health economists.
PromarkerD can predict DKD up to 4 years in advance. A simple test measures 3 plasma biomarkers and 3 clinical factors.
.
About Virtual ISPOR
Join global healthcare leaders as they convene at Virtual ISPOR 2021, the leading global conference for health economics and outcomes research (HEOR), for discussion and dissemination of the latest trends in healthcare.
Themed HEOR: Evolving for Tomorrow’s Challenges, Virtual ISPOR 2021 will analyze opportunities and challenges in HEOR methods, practices, and application including our ability to respond effectively.
This must-attend event provides you with dedicated opportunities to network with your peers, HEOR experts, and thought leaders and to discuss with a global audience how we establish, incentivize, and share value sustainable for health systems, patients, and technology developers. Topics covered include:
.
